Transglutaminase is a mesothelioma cancer stem cell survival protein that is required for tumor formation

Gautam Adhikary; Daniel Grun; H. Richard Alexander; Joseph S. Friedberg; Wen Xu; Jeffrey W. Keillor; Sivaveera Kandasamy; Richard L. Eckert

doi:10.18632/oncotarget.26130

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Transglutaminase is a mesothelioma cancer stem cell survival protein that is required for tumor formation

Gautam Adhikary, Daniel Grun, H. Richard Alexander, Joseph S. Friedberg, Wen Xu, Jeffrey W. Keillor, Sivaveera Kandasamy and Richard L. Eckert _

PDF | HTML | How to cite

Oncotarget. 2018; 9:34495-34505. https://doi.org/10.18632/oncotarget.26130

Metrics: PDF 1461 views | HTML 2823 views | ?

Abstract

Gautam Adhikary1, Daniel Grun1, H. Richard Alexander7, Joseph S. Friedberg4,5, Wen Xu1, Jeffrey W. Keillor6, Sivaveera Kandasamy5 and Richard L. Eckert1,2,3,4

1Departments of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, Maryland, USA

2Department of Dermatology, University of Maryland School of Medicine, Baltimore, Maryland, USA

3Department of Reproductive Biology, University of Maryland School of Medicine, Baltimore, Maryland, USA

4Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland, USA

5Department of Surgery and Division of General and Surgical Oncology, University of Maryland School of Medicine, Baltimore, Maryland, USA

6Department of Chemistry, University of Ottawa, Ottawa, ON, CA

7Department of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA

Correspondence to:

Richard L. Eckert, email: [email protected]

Keywords: mesothelioma; transglutaminase; TGM2; cancer stem cell; EMT

Received: April 23, 2018 Accepted: September 08, 2018 Published: October 02, 2018

ABSTRACT

Mesothelioma is a rare cancer of the mesothelial cell layer of the pleura, peritoneum, pericardium and tunica vaginalis. It is typically caused by asbestos, notoriously resistant to chemotherapy and generally considered incurable with a poor life expectancy. Transglutaminase 2 (TG2), a GTP binding regulatory protein, is an important cancer stem cell survival and therapy resistance factor. We show that TG2 is highly expressed in human mesothelioma tumors and in mesothelioma cancer stem cells (MCS cells). TG2 knockdown or TG2 inhibitor treatment reduces MCS cell spheroid formation, matrigel invasion, migration and tumor formation. Time to tumor first appearance is doubled in TG2 knockout cells as compared to wild-type. In addition, TG2 loss is associated with reduced expression of stemness, and epithelial mesenchymal transition markers, and enhanced apoptosis. These studies indicate that TG2 is an important MCS cell survival protein and suggest that TG2 may serve as a mesothelioma cancer stem cell therapy target.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26130

Publication Alerts

Research Papers:

Transglutaminase is a mesothelioma cancer stem cell survival protein that is required for tumor formation

Abstract